Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry

Abstract

Based on responses of ordering physicians, the CCP report adds meaningful new information to risk assessment for localized prostate cancer patients. Test results led to changes in treatment with reductions and increases in interventional treatment that were directionally aligned with prostate cancer risk specified by the test.